

FOR IMMEDIATE RELEASE:



STATKING Statisticians Involved in Poster On Development of Cancer Diagnostic Test

Cincinnati, OH – December 15, 2011 – Lori Christman and Dennis King, Statisticians at STATKING Clinical Services, were part of a poster session presented at the CHI Biomarker Assay Development Conference in San Diego, CA this past year. The poster focused on the development of statistical models to support a serum sample protein assay for the detection of colon cancer. The data analyses conducted by the STATKING statisticians were successful in moving the diagnostic forward in the development process. The diagnostic test is being developed by Onconome, Inc., Redmond, WA.

The full reference for the poster is:

Brock, R., VanBogelen, R., Xiong, B., Li, L., King, D., and Hoffman, L. (2011). **Quantitative Multiplex Protein Assay for Serum Samples to Rule Out Colon Cancer**, Presented at the CHI Biomarker Assay Development Conference.

About STATKING Clinical Services

STATKING Clinical Services provides clinical trial services (biostatistics, clinical data management, clinical study monitoring, medical writing, safety reporting, project management and clinical trial management) for clinical trials for the regulatory approval of novel drug and medical device products. The company is headquartered in Fairfield, OH. The company has provided support on 12 NDAs and 13 PMAs over the past two decades of service to the pharmaceutical and medical device industries. For more information, visit www.statkingclinical.com.

About Onconome, Inc.

Onconome, Inc. is an in-vitro diagnostics company focusing on the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of various forms of cancer and other major diseases with unmet diagnostic needs. For more information, visit www.onconome.com.

Contact

STATKING Clinical Services

Rod Lashley, Executive Vice President 513-858-2989 x303

rod@statkingclinical.com